Natera, Inc.
Key Metrics
- Previous Close
- $287.47
- 52-Week Range
- $181.00 – $437.41
- Market Cap
- $41.98B
- P/E (TTM)
- —
- EPS (TTM)
- -1.12
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 22.35
- PEG Ratio
- —
- Return on Equity
- -10.55%
- Return on Assets
- -6.79%
- Gross Margin
- 65.14%
- Operating Margin
- -8.54%
- Profit Margin
- -5.66%
- Current Ratio
- 2.81
- Debt/Equity
- 0.13
- Total Debt
- $238.84M
- Free Cash Flow
- $84.54M
- Revenue Growth
- 34.10%
- Earnings Growth
- —
- Enterprise Value
- $41.12B
Market Snapshot
About
Natera is a diagnostics and genetic testing company specializing in cell-free DNA (cfDNA) analysis. The company offers non-invasive prenatal testing (NIPT), oncology testing (Signatera for minimal residual disease detection), organ transplant monitoring (Prospera), and carrier screening, using its proprietary Panorama and SNP-based testing platforms for reproductive health and cancer applications.